Tolerability, pharmacokinetics and pharmacodynamics of once-weekly doses of odanatib in males and postmenopausal females
Latest Information Update: 26 Mar 2013
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Research Laboratories; MSD KK
- 26 Mar 2013 New trial record
- 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.